The company has allotted 3,11,111 equity shares of Rs. 10/- each at an issue price of Rs. 45/- (premium of Rs. 35/- on each equity share) on conversion of warrants issued on preferential basis.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech has allotted 3,11,111 equity shares at Rs. 45 each (face value Rs. 10, premium Rs. 35) following the conversion of warrants previously issued on a preferential basis. The allottee is Kompella Ramakrishna Paramahamsa, belonging to the Promoter Group. The company received Rs. 1.05 crore as application money, representing 75% of the total issue price. As a result, the company's issued and subscribed share capital has risen to Rs. 17.48 crore, divided into 1,74,75,927 equity shares of Rs. 10 each.
This is a routine capital action where a promoter-group entity has converted existing warrants into shares, increasing the shareholding of the promoter group. There is no fresh fundraising from the market, and the impact on retail shareholders is minimal apart from a small dilution from the new share issuance.